HKPD

MKT CAP:$7M

Cellyan Biotechnology Co., Ltd

Market Cap

$7M

Healthcare·Medical - Pharmaceuticals·🇭🇰 Hong Kong·NASDAQ

Healthcare·Medical·🇭🇰·NASDAQ

Stock Price

$0.69-$0.12 (-14.48%)

Apr 21, 2026

Company Details

Cellyan Biotechnology Co., Ltd, an investment holding company, engages in the over the counter (OTC) pharmaceutical business in Hong Kong and Mainland China. The company provides OTC pharmaceutical cross-border procurement and distribution ...

CEO

Chenyu Liang

IPO Date

Jan 15, 2025

Website

www.9zt.hk

Key Metrics TTM

Revenue

$37M

— YoY

Net Income

$1M

EPS (Diluted)

$0.14

Free Cash Flow

$52.2K

Revenue / Share

$3.55

Gross Margin

16.1%

Operating Margin

4.7%

Net Margin

3.5%

FCF Margin

0.1%

P/S

0.2x

P/E

5.4x

Earnings Reports

FY 2025

Aug 14, 2025

$20M+21.7%EPS -$0.00

Q4 2025

Mar 31, 2025

$9M-4.7%EPS -$0.08

Q2 2025

Sep 30, 2024

$11M+58.2%EPS $0.08

FY 2024

Mar 31, 2024

$17M+32.9%EPS $0.18

Q4 2024

Mar 31, 2024

$10MEPS $0.11

Revenue & Profitability

Quarter	Revenue	Gross Profit	Operating Income
Q2 24	$7M	$1M	$308.8K
Q4 24	$10M	$2M	$1M
Q2 25	$11M	$2M	$1M
Q4 25	$9M	$509.6K	-$895.0K

Valuation

Quarter	P/S	P/E
Q2 24	—	—
Q4 24	—	—
Q2 25	—	—
Q4 25	0.3x	9.1x

Operating Cash Flow

Quarter	Operating CF	Free CF
Q2 24	-$83.9K	-$135.6K
Q4 24	-$310.4K	-$311.4K
Q2 25	$753.1K	$712.1K
Q4 25	-$183.9K	-$212.8K

Capital Expenditures

Quarter	CapEx
Q2 24	$51.7K
Q4 24	$1.0K
Q2 25	$41.0K
Q4 25	$28.9K

CapEx

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q2 24	$0	0.0%
Q4 24	$0	0.0%
Q2 25	$0	0.0%
Q4 25	$0	0.0%

OpEx Breakdown

Quarter	SG&A
Q2 24	$994.8K
Q4 24	$894.7K
Q2 25	$881.1K
Q4 25	$1M

War Chest

Quarter	Cash	Short-term Investments	Total
Q4 24	$619.6K	$0	$619.6K
Q2 25	$365.0K	$0	$365.0K
Q4 25	$748.7K	$2M	$3M

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change	YoY Change
Q2 24	7M	—	—
Q4 24	10M	+46.1%	—
Q2 25	10M	0.0%	—
Q4 25	10M	+4.1%	—

Shares Outstanding